Press Releases
New Toolkit Allows Researchers to Test Potential Cancer Targets Directly in Patient-Leukemia Cells Excerpt from the Press Release: PHILADELPHIA, Feb. 26, 2026 /PRNewswire/ — A new CRISPR-based tool that is directly used on patients’ cancer cells can identify genes and regulatory elements driving acute myeloid leukemia (AML), an aggressive blood cancer affecting the bone marrow and…
Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles Excerpt from the Press Release: (Boston, MA – 26 February, 2026) Curium, a world leading nuclear medicine company dedicated to using cutting-edge technology and innovative science to personalize diagnoses and treatments…
Excerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses from the Phase 3 OASIS-HAE and OASISplus studies. Results will be presented at the 2026 American Academy of Allergy, Asthma…
– Onvuzosiran achieved significant and durable reductions of plasma kallikrein levels with a favorable safety profile in Phase 1/2 – – Positive results support ongoing Phase 3 clinical trial – Excerpt from the Press Release: SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) — ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics,…
– Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months – – Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial…
95% of Participants Demonstrated Clinical Improvement with No Device-Related Serious Adverse Events Through 90-Day Follow-Up Excerpt from the Press Release: BOSTON, Feb. 24, 2026 /PRNewswire/ — CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, today announced results from a prospective, multi-center, single-arm clinical study evaluating the safety and clinical outcomes…
Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 Excerpt from the Press Release: WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing…
Excerpt from the Press Release: PRINCETON, N.J., Feb. 20, 2026 /PRNewswire/ — Guerbet, a global specialist in contrast media and solutions for medical imaging, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved a labeling update for Elucirem™ (gadopiclenol) injection. The new indication includes approval for pediatric patients aged 0-2 years…
DARE-HPV development supported by $10 million ARPA-H contract; program targets major unmet need with no FDA-approved therapies Excerpt from the Press Release: SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions,…
Excerpt from the Press Release: MADRID and CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the European Medicines Agency (EMA) has authorized its Clinical Trial Application (CTA) to initiate a Phase II study of…